The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option for patients with metastatic disease. A large trial found the once-daily pill doubled survival rates, offering fresh hope for people who have exhausted other treatments.
The US FDA has approved Revolution Medicines' groundbreaking pancreatic cancer drug after it was shown to double the survival rate of patients with advanced disease in a large trial, offering new hope to those with the deadly cancer.
